This workflow confirms and quantifies 31 drugs of abuse in oral fluid (including THC) in a 4.5‑minute LC run on the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1149">Thermo Scientific Stellar mass spectrometer</a> using full scan + targeted MS2 (tMS2) with both HCD and CID fragmentation. With 1 µL injection and 0.1% formic acid in water/methanol mobile phases, the method supports ~13 samples/hour (up to ~320/day continuous operation) while maintaining confirmation performance via ion ratios.<blockquote><h5>Method at a glance</h5><ul><li>What matrix is tested? Oral fluid</li><li>How many drugs? 31 drugs of abuse (panel includes THC)</li><li>Run time? 4.5 minutes</li><li>Throughput? ~13 samples/hour → up to ~320 samples/day (24‑hour operation)</li><li>Injection volume? 1 µL</li><li>Mobile phases? 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B)</li><li>MS acquisition? Full scan + targeted MS2 (tMS2)</li><li>Fragmentation? Compound‑optimized HCD and CID in the same targeted list</li><li>Confirmation strategy? Ion ratios with ±20% tolerance (typical confirmatory approach)</li></ul></blockquote><h3>Why oral fluid—and why speed matters</h3>Oral fluid is attractive for clinical and forensic toxicology because collection is simple and the matrix aligns well with high‑volume workflows (workplace/occupational, roadside, and other settings). The challenge is building a method that’s simultaneously:<ul><li>Broad enough for today’s drug panels</li><li>Sensitive enough to reach required cutoffs</li><li>Fast enough to keep sample queues under control</li><li>Confirmation‑ready (consistent product ions and ion ratios)</li></ul>A 4.5‑minute method is a practical lever here: compress runtime, raise throughput, and still keep confirmation quality by optimizing MS/MS conditions per compound.<h3>The LC method</h3>A short, efficient separation is the foundation of the workflow:<ul><li>UHPLC system: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/744">Thermo Scientific Vanquish Horizon UHPLC</a></li><li>Column: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/424">Thermo Scientific Accucore Biphenyl</a>, 50 × 2.1 mm, 2.6 µm</li><li>Mobile phase A: 0.1% formic acid in water</li><li>Mobile phase B: 0.1% formic acid in methanol</li><li>Injection volume: 1 µL</li><li>Gradient runtime: 4.5 minutes</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 1: Thermo Scientific Vanquish Horizon UHPLC system." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg 120w," sizes="100vw" width="747" height="969"><h3>The MS method (Full scan + targeted MS2 with HCD + CID)</h3><h5>Acquisition approach</h5>This method uses a “two‑layer” strategy for quantitation + confirmation:<ol><li>Full scan (broad coverage, context, quantitative support)</li><li>Targeted MS2 (tMS2) (confirmation‑focused product ions, ion ratios)</li></ol><h5>The key differentiator: HCD and CID in one targeted list</h5>Instead of forcing every analyte into a single fragmentation style, the method uses both:<ul><li>HCD (beam‑type fragmentation)</li><li>CID (resonance‑type fragmentation)</li></ul><h5>Why that improves method development:</h5>Drugs of abuse span multiple chemistries. A single collision approach often works “okay” for most compounds—but one or two analytes can become persistent problems (weak qualifiers, unstable ion ratios, excess noise). Having both HCD and CID available in one method lets you optimize per compound and move faster.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 2: Thermo Scientific Stellar mass spectrometer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg 245w," sizes="100vw" width="645" height="377"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 3: Full scan &amp; targeted MS2 methods, HCD and collision energies used." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg 245w," sizes="100vw" width="768" height="279"><h3>Why CID + HCD flexibility improves confirmation</h3>In this workflow, HCD performed well for most compounds. But for buprenorphine, HCD produced one dominant product ion with additional low m/z noise and noticeable residual precursor. Using CID generated two high‑intensity product ions and delivered consistent ion ratios across the calibration range.When your confirmation hinges on stable ion ratios, the ability to switch fragmentation mode (not just collision energy) is a method‑development advantage—especially for “problem analytes.”<h3>Controllable ionization</h3>Oral fluid methods often deal with limited sample volume and matrix effects. This workflow pairs low injection volume with ionization control using the Thermo Scientific OptaMax Plus HESI source.<ul><li>The OptaMax Plus HESI source supports high probe temperature capability (up to 650 °C).</li><li>In this study, a vaporizer temperature of 500 °C was used to help achieve sensitivity and improve relative peak areas across drugs of abuse.</li></ul>Why this matters: If you’re injecting only 1 µL, ionization stability and efficiency can be the difference between “meets cutoff” and “misses at LOQ.”<h3>Sample preparation</h3>Oral fluid panels become more challenging when THC is included because most drugs of abuse are basic, while THC is largely neutral, and that can stress extraction chemistry.In this workflow, oral fluid calibrators and samples were extracted using a mixed‑mode approach designed to recover THC alongside other drugs:<ul><li>Calibrators prepared across eight levels (broad dynamic range)</li><li>Extraction performed using mixed‑mode chemistry tips (SCX/WAX) in a dispersive SPE‑style workflow</li><li>Steps automated on a liquid handling platform to support high‑throughput consistency</li><li>Samples dried and reconstituted prior to LC‑MS analysis</li><li>Only 1 µL injected per run</li></ul>Even if your lab uses different automation or consumables, the method structure (fast LC + full scan + targeted MS2 with dual fragmentation) transfers well.<blockquote><h5>Throughput math</h5><ul><li>4.5 minutes per injection → 60 / 4.5 = 13.3 injections/hour</li><li>That’s ~13 samples/hour in typical phrasing</li><li>Over 24 hours: 13.3 × 24 = ~320 samples/day (continuous operation)</li></ul>If you run a single shift, just scale accordingly (e.g., ~106/day for an 8‑hour shift, excluding QC and overhead).</blockquote><h3>Performance summary</h3><h5>Sensitivity and linearity</h5><ul><li>Linearity from LOQs as low as 0.25 ng/mL up to 1,000 ng/mL (panel-dependent)</li><li>For THC specifically: LOQ at 1 ng/mL, with a dynamic range extending to 1,000 ng/mL in this evaluation</li><li>Across the panel, LOQs were reported as lower than recommended confirmation cutoffs referenced in SAMHSA guidance and NSC Tier 1 cutoffs (study-specific outcome)</li></ul><h5>Confirmation via ion ratios</h5><ul><li>Ion ratios evaluated using ±20% tolerance (typical confirmatory acceptance framework)</li><li>The workflow produced consistent ion ratios across calibrator levels for the full panel in this evaluation</li></ul><h5>Case sample comparison (real-world relevance)</h5>When compared against a validated triple quadrupole method for case study samples, the Stellar MS workflow:<ul><li>Confirmed the positive hits observed by the reference method</li><li>Reported a few additional positives for select analytes, attributed to lower LOQs</li><li>Highlighted an operational efficiency point: 1 µL injection in this method versus 20 µL injection in the compared method</li></ul><h3>FAQ</h3><div><div><ol><li>How long does the LC‑MS run take for the 31‑drug oral fluid panel? 4.5 minutes per injection using a short UHPLC gradient. &nbsp;</li><li>How many drugs of abuse can Stellar MS detect in this workflow? 31 drugs of abuse, including THC, using full scan + targeted MS2. &nbsp;</li><li>What MS/MS approach is used? A combined strategy: full scan plus targeted MS2 (tMS2) for confirmation. &nbsp;</li><li>Why use both HCD and CID? Because some analytes fragment better—and produce more stable confirmation ions/ion ratios—under one mode versus the other. Using both increases flexibility and speeds method optimization. &nbsp;</li><li>What injection volume is used? 1 µL of extracted sample. &nbsp;</li><li>What mobile phases are used? 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). &nbsp;</li><li>How many samples can you run per day? At 4.5 minutes/injection, throughput is ~13 samples/hour or up to ~320/day with continuous operation (actual throughput depends on QC and scheduling).</li></ol></div></div><h3>What makes this workflow “easy” to develop on Stellar MS</h3>Here’s the short list of features that directly reduce method‑development friction:<ul><li>HCD or CID in one method → optimize per compound, not compromise</li><li>Fast MS2 acquisition speeds (up to 140 Hz for MS2) → more data points across narrow peaks</li><li>Fast polarity switching (true 5 ms) → supports mixed panels efficiently</li><li>Adaptive RT (real‑time retention time window adjustment) → helps reduce reinjections when retention times drift (e.g., column aging) and supports method transfer from longer to shorter gradients</li><li>OptaMax Plus HESI source control → supports sensitivity at low injection volumes</li></ul>If you’re building a fast oral fluid confirmation workflow—or updating an existing DOA panel—this 4.5‑minute method shows how Stellar MS can combine speed, confirmation-ready MS2, and fragmentation flexibility (HCD + CID) in a single targeted workflow. Reach out to learn how to adapt the targeted list, collision settings, and scheduling strategy to your lab’s cutoffs and throughput goals.<blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#MassSpectrometry #OralFluid #DrugsOfAbuse #MethodDevelopment #HighThroughput</blockquote>

4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS

<h2><a target="_blank" rel="noopener noreferrer" href="https://www.isc2026.org/">ISC 2026</a></h2>The <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/companies/314">International Symposium on Chromatography (ISC)</a> represents the oldest conference series on separation science. ISC symposia have been organised since 1956 in each even year. ISC is one of the premier meetings series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.<h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/events/644">35th International Symposium on Chromatography</a></h4>📆6. - 10. September 2026📍Prague, Czech Republic<h3>REGISTRATION</h3><blockquote>👉<a target="_blank" rel="noopener noreferrer" href="https://www.czech-in.org/cmPortalV15/Account/Login?ReturnUrl=%2FcmPortalV15%2FPortal%2FISC26%2Fnormal">Register HERE for the ISC 2026</a>Late Registration until 25 August 2026</blockquote><h3>INDUSTRY ACTIVITIES</h3><h4>Activity 1: Discussion Session: Industry &amp; Education</h4><ul><li>Monday, 7 September 2026 | 16:30-17:50</li><li>Place: Club A</li><li>Moderators: Tony Edge and Deirdre Cabooter&nbsp;</li></ul><h5>Concept:</h5>This discussion session will explore the relationship between education in separation science in academia and the expectations of industry, focusing on how universities and companies can better collaborate to prepare graduates for successful careers in analytical laboratories and R&amp;D environments. The goal of the session is to provide perspectives from both academia and industry on how education in chromatography and related separation techniques can evolve to better reflect current technological, methodological, and regulatory challenges.<h5>Discussion Topics:</h5><ul><li>Bridging academia and industry: how both sectors perceive current cooperation and where improvements are possible&nbsp;</li><li>Graduate preparedness: which skills and competencies are often missing when entering industrial roles, and in which areas graduates typically excel&nbsp;</li><li>Approaches to teaching separation science: how chromatography and related analytical techniques are taught across different universities and regions&nbsp;</li><li>Industry support for education: examples of collaboration such as internships, industrial placements, joint teaching activities, or access to instrumentation&nbsp;</li><li>Experiences with academia–industry partnerships: what models of cooperation have proven effective in practice&nbsp;</li><li>Future perspectives: how education in separation science should adapt to emerging trends such as automation, digitalization, sustainability, and regulatory requirements&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory remarks from invited speakers representing both academia and industry, followed by an interactive discussion with the audience.<h5>Panelists:</h5><ul><li>Shimadzu&nbsp;</li><li>Novartis&nbsp;</li><li>Jelle De Vos, RIC Group&nbsp;</li><li>Davy Guillarme, University of Geneva&nbsp;</li><li>Caterina Temporini, University of Pavia&nbsp;</li></ul><h4>Activity 2: Career Presentation&nbsp;</h4><ul><li>Monday, 7 September 2026 | 18:00-19:00</li><li>Place: Club A</li><li>Moderators: Adrian Clarke and Martina Catani</li></ul><h5>Concept:</h5>This session will provide an overview of career opportunities in separation science across industry, highlighting the wide range of professional pathways available to graduates and experienced scientists working in chromatography and related analytical disciplines.Participating companies will introduce their organizations, present typical roles involving separation techniques, and share insights into the skills and competencies they seek in candidates. The session is intended to support students, early-career researchers, and experienced professionals interested in exploring career options in industry sectors.<h5>Discussion Topics:&nbsp;</h5><ul><li>Overview of career paths involving chromatography and separation science&nbsp;</li><li>Entry-level opportunities for graduates and PhD holders&nbsp;</li><li>Positions for experienced scientists and technical specialists&nbsp;</li><li>Roles in R&amp;D, analytical development, quality control, regulatory science, application support, and instrument development&nbsp;</li><li>Skills and competencies valued by employers in separation science&nbsp;</li><li>Internships, graduate programs, and early-career development opportunities&nbsp;</li><li>Mobility between academia and industry&nbsp;</li></ul><h5>Format:</h5>Short presentation providing:<ul><li>overview of different carrier paths&nbsp;</li><li>introduction to the company and its activities related to separation science&nbsp;</li><li>examples of typical roles and career progression paths&nbsp;</li><li>information about current or expected hiring needs&nbsp;</li><li>advice for candidates interested in pursuing careers in industry&nbsp;</li><li>the session should include time for informal discussion, allowing participants to interact with company representatives and learn more about specific opportunities.&nbsp;</li></ul><h4>Activity 3: Job Fair</h4><ul><li>Monday, 7 September and Tuesday, 8 September 2026 | 12:30-14:00</li><li>Place: Club A</li><li>Main organizer: Adrian Clarke</li></ul><h5>Concept:</h5>The ISC 2026 Job Fair provides a structured opportunity for direct interaction between companies active in separation science and conference participants seeking career opportunities. The session is designed to facilitate efficient, focused conversations between employers and candidates interested in positions related to chromatography and analytical science.Participating candidates will submit their CV in advance allowing companies to review profiles prior to the event and identify potential matches based on expertise, experience, and career interests.<h5>Format:</h5>The Job Fair will follow a structured rotation format:<ul><li>Each participating company will be assigned a dedicated table&nbsp;</li><li>One company representative will meet candidates individually&nbsp;</li><li>Each candidate will have 5 minutes per meeting to introduce their background and interests&nbsp;</li><li>Participants will rotate between companies at timed intervals&nbsp;</li><li>Session timing will be managed by the organizer, with a signal indicating when to move to the next meeting&nbsp;</li></ul><h5>Candidates:</h5>Participants interested in joining the Job Fair are asked to:<ul><li>submit their CV before August 23rd &nbsp;</li><li>indicate areas of expertise and career interests&nbsp;</li><li>specify whether they are seeking internships, entry-level roles, or experienced positions&nbsp;</li><li>specify if you cannot be available on a certain day e.g. owing to poster presentation&nbsp;</li><li>send these materials to: <a href="mailto:careers@isc2026.org">careers@isc2026.org</a>&nbsp;</li></ul><h5>Companies:</h5>Confirmed participating companies to date include:<ul><li>Novartis&nbsp;</li><li>RIC Group&nbsp;</li><li>Shimadzu&nbsp;</li><li>further companies to be added&nbsp;</li></ul>Potential employers please register your interest to <a href="mailto:careers@isc2026.org">careers@isc2026.org</a> to participate in the speed-dating (first come first served basis).“Jobs position” board will be available in the Careers fair in the foyer in the symposium venue and attendees can visit the company booths in the exhibition hall or discuss with recruiting companies during the conference.<blockquote>Recruiters please send an email with your open positions to <a href="careers@isc2026.org">careers@isc2026.org</a> by the 23rd August and bring the job adverts to post on the jobs board (there will also be the possibility to upload the open positions to the Symposium app).</blockquote><h4>Activity 4: Discussion Session: Artificial Intelligence in Separation Science: From Concept to Practice</h4><ul><li>Tuesday, 8 September 2026 | 16:30-18:00</li><li>Place: Club A</li><li>Moderators: Bob Pirok</li></ul><h5>Concept:</h5>Artificial intelligence (AI) and data-driven approaches are increasingly influencing analytical chemistry, offering new possibilities for method development, data interpretation, process optimization, and decision support. This discussion session will explore how AI is currently being applied in separation science, with a particular focus on practical implementation in industry environments.The session aims to provide a realistic overview of the current state of AI adoption, highlighting both successful applications and remaining challenges. Contributions from industry and academia will help clarify where AI already delivers value, where expectations may exceed current capabilities, and what developments are needed to enable broader implementation.<h5>Discussion Topics:&nbsp;</h5><ul><li>Current applications of AI and machine learning in separation science&nbsp;</li><li>Use of AI in chromatographic method development and optimization&nbsp;</li><li>Data analysis, peak detection, and automated interpretation of complex datasets&nbsp;</li><li>AI-supported troubleshooting and predictive maintenance of analytical instruments&nbsp;</li><li>Integration of AI into regulated environments (e.g., pharmaceutical industry)&nbsp;</li><li>Data requirements, data quality, and standardization challenges&nbsp;</li><li>Comparison between academic developments and real-world industrial implementation&nbsp;</li><li>Barriers to adoption, including regulatory considerations, validation requirements, and transparency of models&nbsp;</li><li>Future outlook: digital laboratories, autonomous method development, and AI-assisted decision-making in analytical workflows&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory remarks from invited speakers representing both academia and industry, followed by an interactive discussion with the audience.<h4>Activity 5: Discussion Session: Sustainability in Separation Science</h4><ul><li>Wednesday, 9 September 2026 | 16:30-18:00</li><li>Place: Club A</li><li>Moderators: Gertrud Morlock</li></ul><h5>Concept:</h5>Sustainability has become an increasingly important priority in analytical science, driving the development of greener methods, reduced solvent consumption, improved energy efficiency, and more responsible laboratory practices. While academic research frequently proposes innovative sustainable approaches, their implementation in industry is often influenced by additional considerations such as robustness, regulatory compliance, cost efficiency, scalability, and long-term reliability.This discussion session aims to explore how sustainability principles are applied in real industrial environments and how collaboration between academia and industry can help translate promising research concepts into practical, validated solutions.By bringing together perspectives from both sectors, the session will highlight opportunities to better align research priorities with industrial needs and identify realistic pathways toward more sustainable separation workflows.<h5>Discussion Topics:&nbsp;</h5><ul><li>Reduction of solvent consumption and the transition to more environmentally friendly mobile phases&nbsp;</li><li>Miniaturized and more efficient separation and extraction techniques&nbsp;</li><li>Energy consumption and efficiency of laboratory processes and analytical instrumentation&nbsp;</li><li>Lifecycle considerations for columns, consumables, and laboratory waste&nbsp;</li><li>Metrics and approaches for measuring and evaluating the “greenness” of analytical methods&nbsp;</li><li>Regulatory constraints and requirements that may limit the implementation of greener analytical workflows&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory contributions from invited speakers representing industry, academia, and technology providers, followed by interactive discussion with the audience.<h5>Panelists:</h5><ul><li>Sébastien Rolle, Shimadzu&nbsp;</li><li>Ken Cook, Thermo Fisher Scientific&nbsp;</li><li>Andreas Otto, Agilent&nbsp;</li><li>Janusz Pawliszyn, University of Waterloo&nbsp;</li><li>Giorgia Purcaro, University of Liège&nbsp;</li></ul>

Industry program at ISC 2026

We are delighted to invite food scientists from academia and industry, representatives of (inter)national agencies, control authorities, governmental and commercial laboratories to attend <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/events/928">RAFA 2026</a> (12th Symposium on Recent Advances in Food Analysis), that takes place 3–6 November 2026 in Prague..<blockquote>👉<a target="_blank" rel="noopener noreferrer" href="https://rafa.easyevent.eu/tickets/">SUBMIT ABSTRACT</a> FOR POSTER PRESENTATION by August 31, 2026Do not miss the opportunity to present your latest results at RAFA 2026.</blockquote><h5>Next deadlines:</h5><ul><li>August 31, 2026: 2nd window – &nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/sponsors_exhibitors_media_partners_info.html">Application for participation as a Sponsor or Exhibitor</a></li><li>September 30, 2026:&nbsp;<ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/registration.html">Registration at the regular rate</a></li><li>Abstract submission – Last minute posters (May not appear in the RAFA 2026 program)</li></ul></li></ul>Since its first edition in 2003, RAFA has grown into a prestigious international event, typically welcoming up to 850 participants from more than 60 countries worldwide, with the support of more than 50 sponsors, exhibitors, media and supporting partners.RAFA 2026 will provide an overview of contemporary trends in the ANALYTICAL &amp; BIOANALYTICAL STRATEGIES IN FOOD QUALITY AND SAFETY CONTROL and discuss the CHALLENGES AND NOVEL APPROACHES IN FOOD AND NATURAL PRODUCTS ANALYSIS.View the <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/invited_speakers.html">list of distinguished speakers</a> who have accepted our invitation to RAFA 2026 and will present current hot topics and future perspectives in food analysis!<blockquote>👉More details on the <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/scientific_programme.html">RAFA 2026 preliminary program</a> can be found HERE.👉OUR <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/about_sponsors_exhibitors_partners.html">SPONSORS, EXHIBITORS, MEDIA and SUPPORTING PARTNERS</a></blockquote>You are kindly invited to join and contribute to our exciting scientific program and unforgettable social events!We look forward to meeting you again in Prague!<ul><li>Prof. Jana Pulkrabova &amp; Dr. Stefan van Leeuwen, Symposium Chairs</li><li>Prof. Michele Suman, Symposium Co-chair</li><li>Prof. Jana Hajslova &amp; Prof. Michel Nielen, Symposium Honorary Chairs</li></ul>

RAFA 2026 - Deadline for Abstract Submission for poster presentation is coming

Article

Product

Events

Application

Food

Video

RAFA provides an overview of contemporary trends in ANALYTICAL & BIOANALYTICAL STRATEGIES IN FOOD QUALITY AND SAFETY CONTROL and discusses CHALLENGES / NOVEL APPROACHES IN FOOD AND NATURAL PRODUCTS ANALYSIS.

Recent Advances in Food Analysis (RAFA)

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

Tadalafil Analysis

Targeted HPLC analysis of tadalafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Tadalafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tadalafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Tadalafil</h4>Tadalafil, widely known under the trade name Cialis, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Tadalafil is clinically used primarily for the treatment of erectile dysfunction and is also used for conditions such as benign prostatic hyperplasia and pulmonary arterial hypertension.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tadalafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tadalafil</li><li>Other name: Cialis</li><li>CAS number: 171596-29-5</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of tadalafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Vardenafil analysis

Targeted HPLC analysis of vardenafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Vardenafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of vardenafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Vardenafil</h4>Vardenafil, marketed under names such as Levitra, Staxyn, and Vivanza, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Vardenafil is clinically used for the treatment of erectile dysfunction. It belongs to the same pharmacological class as <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2519">sildenafil</a>, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2520">tadalafil</a>, and <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2517">avanafil</a>.<h4>Key Features</h4><ul><li>Targeted identification and quantification of vardenafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Vardenafil</li><li>Other names: Levitra, Staxyn, Vivanza</li><li>CAS number: 224785-90-4</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for vardenafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of vardenafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

GCMS/LCMS screening for contamination

GCMS/LCMS screening for identification of contaminants in samples, with the analytical method selected according to sample type.

The GCMS/LCMS Screening for Contamination is a standalone laboratory service designed to identify potential contaminants in a sample using either gas chromatography–mass spectrometry (GCMS) or liquid chromatography–mass spectrometry (LCMS).The appropriate analytical method depends on the sample type. GCMS is used primarily for volatile and semi-volatile compounds, while LCMS is suitable for peptide-related contamination.<h4>About the Screening</h4><ul><li>GCMS screening uses the NIST 2014 mass spectral library to identify a broad range of potentially harmful substances in the product. Detection is limited to volatile and semi-volatile compounds and this method is not suitable for peptide samples. &nbsp;</li><li>LCMS screening is intended for peptide products and can detect contamination with other peptides or degraded peptide. Detection is limited to peptides included in the laboratory’s available reference list.</li></ul>Both methods provide identification of detected contaminants only. Quantitative determination of a detected substance can be offered separately.<h4>Key Features</h4><ul><li>Standalone contamination screening by GCMS or LCMS</li><li>Analytical method selected according to sample type</li><li>GCMS screening for volatile and semi-volatile contaminants</li><li>GCMS identification using the NIST 2014 mass spectral library</li><li>LCMS screening for peptide contamination and degraded peptide</li><li>Identification of detected contaminants</li><li>Quantitative determination available separately after identification</li><li>Suitable for tablets, capsules, liquid solutions, raw materials, and vials depending on the selected method</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: GCMS or LCMS</li><li>Amount of sample required: 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>The analytical method is selected according to the type of sample and the expected contaminants.</li><li>GCMS detection is limited to volatile and semi-volatile compounds and cannot be used for peptide samples.</li><li>LCMS detection is limited to peptides included in the laboratory’s available reference list.</li><li>Both GCMS and LCMS screening provide identification only. Quantitative determination of a detected contaminant is not included in the standard analysis and can be offered separately.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

Sterility Testing (TAMC + TYMC)

TAMC + TYMC microbial testing for aerobic microorganisms, yeasts, and molds in unopened vials, ampoules, and liquid samples.

The Sterility Testing service is designed to assess microbial contamination in suitable samples using Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) cultivation tests.The analysis is intended primarily for unopened peptide vials, ampoules, and other liquid samples where microbial contamination may affect product quality and safety.<h4>About TAMC and TYMC</h4>TAMC determines the total number of viable aerobic microorganisms present in a sample, while TYMC evaluates the presence of viable yeasts and molds.Together, these cultivation-based tests provide an assessment of the overall microbial burden of the sample. Results are reported as Pass or Fail according to the applied acceptance criteria.<h4>Key Features</h4><ul><li>Cultivation-based microbial testing</li><li>Total Aerobic Microbial Count (TAMC)</li><li>Total Yeast and Mold Count (TYMC)</li><li>Suitable for unopened peptide vials, ampoules, and selected liquid samples</li><li>Recommended sample amount of two unopened peptide vials</li><li>Alternative sample formats include two 1 ml ampoules or one 10 ml vial</li><li>Results reported as Pass or Fail</li><li>Average turnaround time of 14 days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC)</li><li>Amount required for the test: Two unopened peptide vials recommended, two 1 ml ampoules, or one 10 ml vial (e.g. oil-based samples)</li><li>Result format: Pass or Fail</li><li>Average turnaround time: 14 days</li></ul><blockquote>Important Notice<ul><li>Unopened vials or ampoules are required to minimise the risk of contamination during shipping and handling.</li><li>Submitting less than the recommended sample amount is possible, but it may affect the reliability of the results.</li><li>This test is not recommended for oral products, as oral dosage forms are not generally required to be sterile for safe use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

2,4-Dinitrophenol (DNP) Analysis

Targeted HPLC analysis of 2,4-dinitrophenol (DNP) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The 2,4-Dinitrophenol (DNP) Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 2,4-dinitrophenol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About 2,4-Dinitrophenol (DNP)</h4>2,4-Dinitrophenol (DNP) is a synthetic chemical compound that acts as an uncoupler of oxidative phosphorylation, disrupting normal cellular energy production and increasing heat generation.DNP has historically been investigated for several industrial and biological applications but is highly toxic and is not approved as a weight-loss drug. Exposure can cause serious and potentially life-threatening adverse effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of 2,4-dinitrophenol (DNP)</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: 2,4-Dinitrophenol</li><li>Other name: DNP</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for 2,4-dinitrophenol (DNP). It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of DNP required for evaluation is 20 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>DNP is a highly toxic compound. Laboratory analysis should not be interpreted as confirmation that a product is safe for human consumption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

5-Amino-1-methylquinolinium Analysis

Targeted HPLC analysis of 5-Amino-1-methylquinolinium in pills, tablets, capsules, and raw API powders for identity and amount determination.

The 5-Amino-1-methylquinolinium Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 5-Amino-1-methylquinolinium in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by mass-by-mass purity in %. Please note that 5-Amino-1-methylquinolinium is not a peptide, and peptide purity is therefore not determined.<h4>About 5-Amino-1-methylquinolinium</h4>5-Amino-1-methylquinolinium, also known as 5A1MQ or 5-Amino-1MQ, is a small-molecule research compound investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide.NNMT is an enzyme involved in nicotinamide and cellular methylation metabolism. 5-Amino-1-methylquinolinium has been studied primarily in preclinical research related to cellular metabolism and adipose tissue biology.<h4>Key Features</h4><ul><li>Targeted identification and quantification of 5-Amino-1-methylquinolinium</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format reported as purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: 5-Amino-1-methylquinolinium</li><li>Other names: 5A1MQ, 5-Amino-1MQ</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>5-Amino-1-methylquinolinium is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for 5-Amino-1-methylquinolinium. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>Iodide/Chloride Analysis</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

AICAR analysis

Targeted HPLC analysis of AICAR in finished lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The AICAR Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of AICAR in finished lyophilised vials and raw active pharmaceutical ingredient (API) powders.For finished vials, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). AICAR is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About AICAR</h4>AICAR is a small-molecule research compound widely used in studies of cellular energy metabolism and AMP-activated protein kinase (AMPK) signalling. After cellular uptake, AICAR riboside can be phosphorylated to ZMP, an AMP analogue that can activate AMPK.AICAR has been investigated extensively in preclinical research examining metabolic regulation, glucose and lipid metabolism, and cellular responses to changes in energy availability. Its effects are not exclusively mediated through AMPK, and additional AMPK-independent mechanisms have also been described.<h4>Key Features</h4><ul><li>Targeted identification and quantification of AICAR</li><li>Suitable for finished lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for finished vials reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: AICAR</li><li>Testing method: HPLC</li><li>Result format for finished vial: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for finished vial: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>AICAR is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For finished products, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a> (TAMC and TYMC)</li><li>Additional Laboratory Report</li></ul>

BAC Water (Benzyl Alcohol) Analysis

HPLC analysis of benzyl alcohol in bacteriostatic water, including confirmation and concentration determination in mg/ml.

The BAC Water (Benzyl Alcohol) Analysis is a targeted laboratory test designed to confirm the presence and determine the concentration of benzyl alcohol in bacteriostatic water.The analysis is performed by HPLC, with results reported in milligrams of benzyl alcohol per millilitre of sample.<h4>About Benzyl Alcohol</h4>Benzyl alcohol is an aromatic alcohol commonly used as a preservative in pharmaceutical and laboratory formulations. In bacteriostatic water, it is added to help inhibit microbial growth after a vial has been opened.This analysis specifically determines the concentration of benzyl alcohol in the submitted liquid sample.<h4>Key Features</h4><ul><li>Targeted identification and quantification of benzyl alcohol</li><li>Designed for bacteriostatic water and similar liquid samples</li><li>Analysis by HPLC</li><li>Results reported in mg/ml</li><li>Minimum concentration for evaluation: 1 mg/ml</li><li>Minimum sample amount: 1 ml</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Benzyl Alcohol</li><li>Testing method: HPLC</li><li>Minimum concentration of target compound for evaluation: 1 mg/ml</li><li>Result format: mg/ml</li><li>Minimum sample amount: 1 ml</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for benzyl alcohol in liquid samples. It does not automatically screen the sample for other preservatives, active compounds, contaminants, or undeclared substances.</li><li>Samples containing less than 1 mg/ml benzyl alcohol may not be reliably evaluated within the standard scope of the analysis.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a> (TAMC and TYMC)</li></ul>

BAM-15 analysis

Targeted HPLC analysis of BAM-15 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The BAM-15 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of BAM-15 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). BAM-15 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About BAM-15</h4>BAM-15 is a small-molecule research compound that acts as a mitochondrial uncoupler. It increases proton transport across the inner mitochondrial membrane, thereby uncoupling nutrient oxidation from ATP production and altering cellular energy metabolism.BAM-15 has been investigated mainly in preclinical research focused on mitochondrial function, energy expenditure, glucose and lipid metabolism, and related metabolic processes<h4>Key Features</h4><ul><li>Targeted identification and quantification of BAM-15</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: BAM-15</li><li>Other name: BAM15</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>BAM-15 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for BAM-15. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Clenbuterol Analysis

Targeted HPLC analysis of clenbuterol in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Clenbuterol Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clenbuterol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Clenbuterol</h4>Clenbuterol is a synthetic beta-2 adrenergic agonist with bronchodilator activity. It stimulates beta-2 adrenergic receptors and can affect smooth muscle tone, cardiovascular function, and metabolic processes.Clenbuterol has been used therapeutically in some countries for respiratory conditions, but it is not approved for human use in many jurisdictions. It is also known for non-medical use related to its stimulant and metabolic effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of clenbuterol</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Clenbuterol</li><li>Other name: Clen</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for clenbuterol. It does not automatically screen the sample for other beta-2 agonists, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of clenbuterol required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on Laboratory analysis - page 4

Related content

4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS

RAFA 2026 - Deadline for Abstract Submission for poster presentation is coming

Industry program at ISC 2026